Mirati To Present Updated Clinical Data at ESMO Congress 2023
- Adagrasib shows promising efficacy in combination with pembrolizumab in front line setting
- None.
Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC
Data follows recent inclusion of the adagrasib in combination with an EGFR inhibitor listed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancers
"Adagrasib is the first targeted KRASG12C inhibitor to show promising efficacy and early signs of durability in combination with an immune checkpoint inhibitor in the front line setting," said Alan Sandler, M.D. chief medical officer, Mirati Therapeutics. "Based on this compelling data, we plan to initiate enrollment in a global Phase 3 study in the fourth quarter evaluating adagrasib in combination with pembrolizumab in patients with KRAS G12C -mutated NSCLC with PD-L1 ≥
Presentation Title: KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Author: Marina C. Garassino
Abstract Number: 5053
Session: Proffered Paper session - NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:40-16:50 CEST and 7:40-7:50 a.m. PST
Presentation Title: Adagrasib With or Without Cetuximab in Patients With KRASG12C-Mutated Colorectal Cancer (CRC): Analysis of Tumor Biomarkers and Genomic Alterations
Author: Meredith S. Pelster
Abstract Number: 3402
Session: Proffered Paper Session 1 – Gastrointestinal tumours, lower digestive
Presentation Date/Time: Sat, 10/21/2023 15:25-15:35 CEST and 6:25-6:35 a.m. PST
Presentation Title: SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Author: Hossein Borghaei
Abstract Number: 5049
Session: Proffered Paper session - NSCLC, metastatic
Presentation Date/Time: Fri, 10/20/23 16:00-16:10 CEST and 7:00-7:10 a.m. PST
Symposium: Near the conclusion ESMO 2023, Mirati is also sponsoring New Horizons in the Treatment of KRAS-Driven NSCLC and GI Cancers, an industry satellite symposium with Luis Paz-Ares, M.D., Ph.D. of Hospital Universitario 12 de Octubre, Aparna Parikh, M.D. of Mass General Cancer Center, Harvard Medical School and Keith Kerr, MB ChB, FRCPath, FRCPE of NHS Grampian. The symposium will discuss advances in targeting KRAS-driven NSCLC with a focus on the current status and future development of KRASG12C inhibitors, review the current status of targeted therapies for GI cancers and discuss the importance of timely molecular testing. The symposium will be held on October 23 from 13:00-14:30 CEST in the Valencia Auditorium, Hall 10, IFEMA Madrid.
About Mirati Therapeutics, Inc.®
Mirati Therapeutics, Inc. is a commercial stage research and development biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.
For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI® (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor), Mirati's technologies and Mirati's other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.
Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-to-present-updated-clinical-data-at-esmo-congress-2023-301940962.html
SOURCE Mirati Therapeutics, Inc.
